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The host dNTP hydrolase SAMHD1 acts as a viral restriction factor to inhibit the replication of several retroviruses
and DNA viruses in non-cycling human immune cells. However, understanding the physiological role of mammalian
SAMHD1 has been elusive due to the lack of an animal model. Two recent studies reported the generation of
samhd1 knockout mouse models for investigating the restriction of HIV-1 vectors and endogenous retroviruses
in vivo. Both studies suggest that SAMHD1 is important for regulating the intracellular dNTP pool and the intrinsic
immunity against retroviral infection, despite different outcomes of HIV-1 vector transduction in these mouse models.
Here I discuss the significance of these new findings and the future directions in studying SAMHD1-mediated retroviral
restriction.Introduction
The dNTP hydrolase SAMHD1 functions as a retroviral
restriction factor in human non-cycling myeloid cells
and resting CD4+ T-cells [1-7]. The molecular mecha-
nisms by which SAMHD1 restricts retrovirus replication
in non-cycling cells are not fully understood. Although
SAMHD1-mediated HIV-1 restriction involves the de-
pletion of the intracellular dNTP pool in non-cycling
cells [4,5,7], recent studies revealed that phosphorylation
of human SAMHD1 protein negatively regulates its
HIV-1 restriction function [8-10]. The lack of SAMHD1
protein expression in humans due to SAMHD1 gene
mutations can result in a rare, but severe autoimmune
disease called Aicardi-Goutieres syndrome (AGS). AGS
is associated with elevated type I interferon (IFN) pro-
duction and likely is due to an innate immune response
to accumulated nucleic acids in the cell [11]. Despite the
rapid research progress in understanding the molecular
mechanisms of SAMHD1-mediated retroviral restriction,
characterization of the physiological role of SAMHD1
in vivo has been elusive due to the lack of an animal
model.
Generating a samhd1 knockout (KO) mouse model
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stated.SAMHD1 in vivo [12,13]. Alternative splicing generates
two isoforms of mouse SAMHD1 (mSAMHD1) proteins
[12], which differ at the C-terminus and share about 72-
74% identity with human SAMHD1 (hSAMHD1).
mSAMHD1 possesses a similar dNTP hydrolase activity
and also restricts in vitro HIV-1 infection as hSAMHD1
[4]. Both mSAMHD1 isoforms can block in vitro HIV-1
or SIV infections when they are ectopically expressed in
a human monocytic cell line (U937) that does not ex-
press endogenous hSAMHD1 and is differentiated into
non-cycling, macrophage-like cells [4]. Interestingly, two
recent studies reported the generation of samhd1 KO
mouse models for studying retroviral restriction in vivo,
while the effects of SAMHD1 deficiency on HIV-1 vec-
tor transduction in these mice appeared to be distinct
[12,13]. The new findings and implications of these two
studies are analyzed and discussed below.
New findings and implications
Generation of samhd1-null mice
Two studies by Rehwinkel et al. and Behrendt et al. gen-
erated conditional knockout strains in a mixed or a pure
C57BL/6 background and obtained the samhd1-null
mice by deleting exon 2 of the gene [12,13]. In both
cases, homozygous samhd1-null mice had no detectable
amount of SAMHD1 protein in bone marrow-derived
dendritic cells (BM-DCs), primary mouse embryonic fi-
broblasts (MEFs), or splenocytes [12,13]. It is possible
that these two samhd1-null mouse strains may haveis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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these studies [12,13]. Unlike the severe autoimmune dis-
ease in SAMHD1-deficient human patients with AGS
[11], the samhd1-null mice were healthy beyond the age
of 96 weeks [12] or up to 70 weeks [13], respectively.
Neither SAMHD1-deficient mouse strain developed de-
tectable pathology or autoimmunity [12,13], suggesting
that mSAMHD1 function might be redundant or not
directly involved in the innate immune responses to nu-
cleic acids in mice. It also is conceivable that other trig-
gers (such as cytokines, dysfunction of immune cells, or
environmental factors) in human AGS patients may con-
tribute to the disease pathogenesis in addition to the
genetic deficiency of SAMHD1.
Increased intracellular dNTP pool in samhd1-null mice
Using the samhd1-null mouse models, both studies con-
firmed that mSAMHD1 acts as a dNTP hydrolase
in vivo to reduce intracellular dNTP concentrations in
multiple cell types [12,13] (Figure 1). Compared with
cells from wild-type mice, the intracellular dNTP con-
centrations were significantly increased in BM-DCs,
bone marrow-derived macrophages (BM-DMs) [12,13],
B-cells, T-cells, and MEFs [13] derived from samhd1−/−
mice. For example, the intracellular dTTP levels in BM-
DCs from samhd1−/− mice were quantified in both studies
using different methods and showed an approximately 5-Figure 1 HIV-1 infection and intrinsic immune response in SAMHD1-d
significantly increased in multiple cell types from samhd1-null mice compa
hydrolase in vivo to reduce the intracellular dNTP pool. Spontaneous transc
observed in several cell types and tissues from samhd1-null mice compared
regulating the IFN signaling pathway in vivo, although the innate sensor th
SAMHD1-deficient mice or derived cells with HIV-1 vectors is increased rela
on the affinity for dNTPs of the HIV-1 RT and the experimental conditions ifold increase compared with those from wild-type mice
[12,13]. Of note, the dTTP level in BM-DCs (0.5 μM)
from wild-type mice reported by Rehwinkel et al. was
5-fold higher than that in human monocyte-derive DCs
(~ 0.1 μM) from healthy donors [7]. This comparison sug-
gests that dNTP levels in mouse cells are likely higher
than those in human cells; however, it is difficult to dir-
ectly compare these results since different approaches and
cell types were used in independent experiments.
Induction of type I IFN-stimulated genes in samhd1-null
mice
Spontaneous and significant induction of mRNA expres-
sion of IFN-stimulated genes (ISGs) was observed in
multiple cell types and tissues from samhd1-null mice
compared with wild-type mice [12,13]. These results and
the previous study by Rice et al. [11] suggest that
SAMHD1 is a negative regulator in suppressing IFN-
induced innate immune responses (Figure 1). Using a
sensitive IFN bioassay, Rehwinkel et al. showed in-
creased mRNA expression of several ISGs and the pro-
inflammatory cytokine TNFα in spleens, macrophages
and fibroblasts from samhd1-null mice compared with
those from wild-type mice [12]. However, SAMHD1-
deficient mice did not display detectable amounts of cir-
culating IFN proteins or upregulation of ISG products
in their sera or most tissues examined [12]. Usingeficient mouse cells. Intracellular dNTP concentrations are
red with control cells, indicating that mSAMHD1 acts as a dNTP
riptional induction of type I IFN-stimulated genes (ISGs) has been
with wild-type mice. Therefore, mSAMHD1 might play a role in
at triggers the spontaneous ISG responses is unclear. Transduction of
tive to wild-type mice or murine cells, which appears to be dependent
n these studies (refer to Table 1). RT, HIV-1 reverse transcriptase.
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that 123 ISGs were significantly up-regulated (85% of 141
genes showed signficiant up-regulation) in SAMHD1-
deficient BM-DMs compared with those from control
mice [13]. The up-regulation of ISG transcripts was
dependent on IFNβ since crossing SAMHD1- and IFNβ-
deficient mice prevented spontanous transcriptional acti-
vation of the ISGs [13]. Compared with wild-type mouse
MEFs or BM-DMs, no difference of INFα induction was
observed in SAMHD1-deficient cells treated with in vitro-
transcribed RNA [12]. Notably, the undetectable type I
IFN protein in the sera from SAMHD1-deficient mice
[12] did not mirror the elevated levels of serum IFNα
found in some human AGS patients [3,11], suggesting that
SAMHD1 deficiency in mice is not sufficient to enhance
the production or release of type I IFNs. Furthermore,
similar levels of the induced INFα were detected in the
sera of wild-type and SAMHD1-deficient mice infected
with encephalomyocarditis virus, an RNA virus that can
trigger INFα production [12]. These data suggest that
mSAMHD1 deficiency is not sufficient to trigger IFN in
response to nucleic acids or RNA virus infection in
mice.
Increased HIV-1 vector transduction in samhd1-null mice
Human blood monocytes and resting CD4+ T-cells from
SAMHD1-deficient AGS patients are more susceptible
to in vitro HIV-1 infection compared with normal cells
[3,5,6], suggesting that hSAMHD1 contributes to HIV-1
restriction in non-cycling immune cells through an in-
trinsic mechanism. Despite significantly increased intra-
cellular dNTP levels in SAMHD1-deficient mouse cells,Table 1 Comparison of viral infections of samhd1 KO and wild
In vitro HIV-1 vector infection of cells from samhd1 KO mice compared
with wild-type mice
In vivo HIV-1 vector transduction of samhd1 KO mice








Friend virus infection (a type of MLV)
Endogenous Mo-MLV replication or mouse retrotransposons
Encephalomyocarditis virus infection (a mouse RNA virus that induces IFNα)
*dpi, days post-infection; #ND: not done.Rehwinkel et al. did not observe any changes in single-
cycle infection or transduction with HIV-1 or Moloney
murine leukemia virus (Mo-MLV) vectors in samhd1-null
mice or derived cells when compared with wild-type mice
or cells [12]. Rehwinkel et al. interpreted that the lack of
HIV-1 restriction in wild-type mouse cells was likely at-
tributable to higher dNTP concentrations (~ 0.5 μM) than
the KM (~ 0.07 μM) of HIV-1 reverse transcriptase (RT).
However, a ~5-fold increase in HIV-1 in vitro infection
was evident in BM-DMs, BM-DCs and MEFs from
samhd1-null mice using a vector expressing a mutant
HIV-1 RT (V148I), which required higher levels of dNTPs
relative to wild-type RT [12]. In line with this observation,
Lahouassa et al. showed that the V148I RT mutant HIV-1
was approximately 6-fold less infectious in SAMHD1-
sufficient human monocyte-derived macrophages com-
pared with wild-type HIV-1 [4]. Furthermore, compared
with wild-type mice, in vivo infection of samhd1-null mice
with the mutant HIV-1 vector increased the viral trans-
duction of splenocytes by ~8-fold and significantly en-
hanced transduction of myeloid and lymphoid cells as well
as non-hematopoietic cells [12]. These results suggest that
mSAMHD1 inhibits in vivo HIV-1 vector transduction by
reducing the intracellular dNTP pool, which is in agree-
ment with previous in vitro studies indicating that over-
expressed mSAMHD1 blocks HIV-1 infection in differen-
tiated human monocytic U937 cells [4].
In contrast to no effect on the transduction of
samhd1-null mice with an HIV-1 vector expressing a
wild-type RT reported by Rehwinkel et al. [12], Behrendt
et al. used a different HIV-1 vector expressing a wild-
type RT (Table 1) and demontrated a ~3- to 8-fold-type mice and derived cells [12,13]
Rehwinkel et al. [12] Behrendt et al. [13]
• No effect on the infectivity of HIV-1
vector (wild-type RT) at 1–2 dpi*
• 5-fold increase of HIV-1 RT mutant
(V148I) vector infection in BM-DC,
BM-DMs, and MEFs
• ~5-fold increased infectivity
of HIV-1 vector (wild-type RT)
in BM-DCs at 3 dpi*
• Likely dependent on HIV-1
vector strains
• No effect on HIV-1 vector (wild-type RT)
at 5–6 dpi*
• 3-8-fold increase of HIV-1 RT mutant
(V148I) in multiple cell types at 5–6 dpi*
• ~4-fold increased HIV-1 vector
transduction (wild-type RT)
in multiple cell types at 3 dpi*
• pRRLsin.eGFP/ pCMVΔ8.2 vector
(encoding Vif, Vpr, Vpu, and Nef)
• HIV-1-based pCSGW/ p8.91 vector
(no accessory genes)
• HIV-1NL4-3 based GFP reporter
vector (pHR.CMVGFP/
pCMVDR8.91)
• Intravenously with 5 × 107 or 1 × 108
293T cell infectious units
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and CD8+ T-cells, B-cells, dendritic cells, and macro-
phages in samhd1-null mice compared with those in
wild-type mice [13]. Moreover, in vitro infection of BM-
DCs from samhd1-null mice using two different HIV-1
vectors expressing wild-type RT also showed a ~5-fold
increase compared with control cells. Reconstitution of
mSAMHD1 expression in BM-DCs from samhd1-null
mice restored HIV-1 restriction, suggesting that
mSAMHD1 contributes to the intrinsic anti-HIV-1
mechanisms in vivo, at least in part [13]. The discrep-
ancy in results of HIV-1 transduction in these two
strains of SAMHD1-deficient mice might be attributed
to the different experimental approaches and conditions
used in these studies [12,13] (Table 1). The viral infec-
tions and transductions in SAMHD1-deficient mice or
derived cells reported in these two studies are compared
in Table 1.
SAMHD1 does not affect endogenous retroviruses or
retrotransposons in mice
It is conceivable that SAMHD1 may block endogenous
retroviruses or retrotransposons by reducing the intra-
cellular dNTP pool through its hydrolase activity.
Rehwinkel et al. showed that SAMHD1 deficiency did
not affect RNA levels of mouse long terminal repeat
(LTR) retrotransposons and endogenous retroviruses (in-
cluding MusD, IAP, Mu-ERV-L and m-poly-MLV) or the
replication of endogenous Mo-MLV in BM-DCs and
MEFs, or in lung and spleen tissues [12]. Therefore,
mSAMHD1 appears to be independent of in vivo control
of endogenous retroviruses and LTR retrotransposons in
mice [12]. However, it is also possible that SAMHD1
may inhibit other retrotransposons or endogenous retro-
viruses in humans or mice. A recent study by Zhao et al.
reported that diverse mammalian SAMHD1 proteins po-
tently inhibited the non-LTR retrotransposon LINE-1
and LINE-1-mediated Alu/SVA retrotransposition in
dividing human cell lines, suggesting that SAMHD1 may
act as a cellular regulator of the conserved LINE-1 activ-
ity in mammals [14].
Conclusions
The studies by Rehwinkel et al. and Behrendt et al. have
established samhd1-null mouse models to better under-
stand the physiological role of SAMHD1 in vivo [12,13].
Although SAMHD1 is not essential for mouse survival
or development, it functions as a dNTP hydrolase
in vivo and reduces the intracellular dNTP pool. The
new findings from these studies suggest that mSAMHD1
can restrict lentiviruses in vivo through an evolutionarily
conserved intrinsic mechanism, by decreasing intracellular
dNTP concentrations [12,13]. Moreover, SAMHD1 defi-
ciency in mice results in IFNβ-dependent transcriptionalup-regulation of type I IFN-inducible genes and type I IFN
signature in certain tissues and cell types [12,13], suggest-
ing an important role of SAMHD1 in regulating innate
immunity. The SAMHD1-deficient mouse model could be
used as a potential tool to investigate the mechanisms of
pathogenic type I IFN responses in autoimmune diseases
in humans [12,13].
Future directions
The molecular mechanisms underlying mSAMHD1-
mediated restriction of HIV-1 in vivo are only starting to
be investigated. Previous in vitro studies using cultured
human myeloid cells and resting CD4+ T-cells have
demonstrated that hSAMHD1 inhibits the accumulation
of late reverse transcription products of HIV-1 [1,2,4-7],
which is correlated with the reduced intracellular dNTP
pool in these non-cycling cells [4,5,7]. It is important to
know whether the increased HIV-1 gene expression in
cells derived from samhd1-null mice is due to the in-
creased levels of late reverse transcription products during
HIV-1 cDNA synthesis, which has not been addressed in
either study using SAMHD1-deficient mice [12,13]. How-
ever, current evidence suggests that decreasing the intra-
cellular dNTP levels by SAMHD1 might be necessary, but
not sufficient for HIV-1 restriction [8-10]. Recent studies
indicate that cell differentiation-dependent phosphoryl-
ation of hSAMHD1 at residue T592 negatively regulates
its anti-HIV-1 function [8-10], but not dNTPase activity
[9,10]. It would be interesting to know whether phosphor-
ylation of mSAMHD also affects its hydrolase activity and
anti-retroviral function.
The cellular sources of type I IFN and the innate sen-
sors that trigger the spontaneous IFN response in
SAMHD1-deficient mice remain unclear [12,13]. Com-
paring cells types that produce type I IFNs in the various
KO mouse models of AGS-associated genes and cells
from human AGS patients can provide a means to iden-
tify the cellular sources of IFN production and the mo-
lecular mechanisms underlying spontaneous IFN
induction in SAMHD1-deficient mice. These studies
may help reveal the cellular and molecular mechanisms
by which SAMHD1 modulates IFN and ISG expression.
SAMHD1-mediated HIV-1 restriction in human mye-
loid cells and resting CD4+ T-cells has been proposed as
an immune evasion strategy for HIV-1 to avoid antiviral
innate and adaptive immune responses and establish per-
sistent infection [1,5,7]. SAMHD1 and Vpx interactions
may contribute to the distinct pathogenic outcomes of
HIV-1 and HIV-2 infection in humans. Additional in vivo
studies using the macaque model and SIV infection as well
as the humanized mouse model and HIV-1 infection could
be useful to test this hypothesis.
Interestingly, recent genome-wide sequencing projects
identified low frequencies of samhd1 somatic mutations
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lung adenocarcinoma, myeloma, medulloblastoma, glio-
blastoma, pancreatic, and breast and colorectal cancers
(discussed in [12,15]). de Silva et al. reported significant
down-regulation of SAMHD1 expression in peripheral
blood mononuclear cells from T-cell lymphoma patients
compared with those from health donors, which corre-
lated with significantly increased levels of samhd1 pro-
moter methylation [15]. These studies suggest a
potential role of SAMHD1 silencing in cancer develop-
ment and the involvement of epigenetic mechanisms in
regulating SAMHD1 expression. Therefore, in conjunc-
tion with other gene KO mouse models targeting tumor
suppressors, the SAMHD1-deficient mouse models pro-
vide an important tool to explore the potential role of
SAMHD1 in cancer.
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